Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

Background A meta-analysis is presented of cardiovascular outcome trials (CVOTs)
comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on …

Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular …

A meta‐analysis of cardiovascular outcome trials (CVOTs) comparing glucagon‐like peptide‐
1 receptor agonists (GLP‐1RAs) and placebo concerning cardiorenal outcomes in patients …

Background GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) have
shown to reduce the risk of major adverse cardiovascular events (MACE), death and …

Background Major prospective randomized clinical safety trials have demonstrated
beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and …

Objective. Data from randomized clinical trials with metabolic outcomes can be used to
address concerns about potential issues of cardiovascular safety for newer drugs for type 2 …

ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …